Beta Bionics Q3 Revenue Rises 30%, 2026 Outlook Narrows

Beta Bionics reported a 30% year-over-year increase in third-quarter revenue, while higher operating expenses contributed to a wider net loss. The diabetes technology company also narrowed its 2026 revenue outlook to $124 million to $126 million, raising the bottom of its previous $121 million-to-$126 million range, even as it anticipates that prospective customers waiting for its Mint patch pump could defer as much as $8.5 million of fourth-quarter revenue.

Revenue rose to $35.5 million for the quarter ended September 30, 2026, from $27.3 million a year earlier and $32.0 million in the second quarter. Gross profit increased to $20.3 million from $15.1 million a year ago. Gross margin was 57%, compared with 55% in the prior-year period and 59% in the preceding quarter.

The company remained loss-making as it continued to invest in operations and product development. Total operating expenses increased to $46.9 million from $32.2 million a year earlier. The GAAP net loss widened to $24.4 million from $14.2 million, while the adjusted EBITDA loss increased to $18.9 million from $12.2 million. Beta Bionics recorded $6.7 million of stock-based compensation expense during the quarter.

Pharmacy Access and Patient Mix

Beta Bionics said approximately 69% of new patient starts in the quarter came from people previously using multiple daily injections. Pharmacy reimbursement accounted for a percentage in the high 30s of new patient starts.

Management cited stable utilization and retention across both durable medical equipment and pharmacy channels. It also expects contributions from at least 20 sales territories added during the first half of 2026, along with additional formulary agreements and deeper adoption of the iLet system by individual health plans.

For the full year, the company expects 37% to 39% of new patient starts to come through the pharmacy channel, unchanged from its previous guidance. It projects a gross margin of 58.5% to 59.5%, also unchanged. The outlook assumes continued cost discipline and better absorption of manufacturing overhead as production scales.

Mint Launch and Product Pipeline

The FDA cleared Beta Bionics’ Mint patch pump in September 2026, and the company expects a full U.S. commercial launch in the first quarter of 2027. Ahead of that launch, management expects some prospective iLet users to delay starting therapy, resulting in potential fourth-quarter revenue deferrals of up to $8.5 million.

Beta Bionics also expects to launch an iLet integration with Senseonics’ Eversense 365 continuous glucose monitoring system in the fourth quarter of 2026. The company plans to initiate a pivotal trial during the same quarter for a next-generation fully closed-loop algorithm that eliminates the need for meal announcements.

Enrollment has been completed for a U.S. pivotal trial evaluating the iLet for adults with type 2 diabetes. Subject to regulatory clearance, the company expects the product’s indications for use to expand around mid-2027.

A new 510(k) submission for its 3D Intelligence technology is expected in mid-fourth-quarter 2026. Beta Bionics said commercial launches of iLet 3D and Mint 3D are expected around mid-2027, subject to clearance, although a launch as early as the fourth quarter of 2026 remains possible.

Capital and Execution Risks

Beta Bionics raised approximately $161.3 million in net proceeds through a public offering in September. Its longer-term priorities include expanding sales territories and pharmacy coverage, entering additional markets and indications, and advancing its bihormonal system.

Those plans remain subject to significant execution and regulatory uncertainty. Several product candidates have not received FDA authorization or clearance, and the company cautioned that clinical development, regulatory reviews, commercialization, reimbursement initiatives and market expansion may not proceed on the expected timelines. Beta Bionics also operates in what it described as a competitive and rapidly changing environment, while material changes in items excluded from its non-GAAP guidance could significantly affect future GAAP results.